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Approximately  300  million  people  worldwide  are  persistently  infected  with  the  hepatitis  B virus  and
are  at  risk  of  developing  hepatocellular  carcinoma  and liver  cirrhosis,  which  can  progress  to end-stage
liver  disease.  Despite  the effectiveness  of the  current  vaccination  policy,  the  prevalence  of the disease
remains  high,  and  the burden  for health  services  is considerable.  The  currently  available  antiviral  strate-
gies are  either  poorly  effective  or  only  effective  for non-curative  suppression  of viral  replication.  Recenthronic hepatitis B
ure
mmune response
irology
efforts  have  been  focused  on improving  the  cure  rate  for chronic  hepatitis  B and  developing  strategies  to
eliminate  infected  cells.
Several  approaches  are  under  evaluation,  and  these  include  targeting  the  virus  at  different  stages  of  its
life  cycle  and boosting  the  antiviral  immune  response.  This  article  reviews  these  latest  approaches  and
comments  on their  feasibility  and potential  translation  into  clinical  applications.
 Gast©  2015  Editrice
. Introduction
Hepatitis B virus (HBV) infection is a major global health
roblem, despite the availability of effective vaccine prophylaxis.
ccording to the latest World Health Organization (WHO) reports,
n estimated 240–280 million people are chronic hepatitis B (CHB)
arriers, among whom the disease occurs with a very high burden,
s approximately 1 million people die every year from CHB-related
isease [1,2].
Dramatic improvements in the efﬁcacy of the treatment of
hronic hepatitis C were made possible by the availability of highly
otent direct antiviral agents, which created an expectation of sim-
lar results being achieved in chronic HBV.
Despite the availability of highly effective direct antiviral agents
or HBV for the last 17 years, a cure cannot be achieved in most cases
ecause of the peculiar features of this virus.
In fact, the viral life cycle of HBV involves the formation of
articularly stable episomal minichromosomes, covalently closed
ircular DNA (cccDNA) molecules, which serve as a template for
ranscription and a reservoir for future replication cycles [3,4].
urthermore, the HBV genome is able to integrate into the host
enome, thus reinforcing viral antigen production and favouring
BV oncogenesis [5].
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The inability to arrest this complex replicative machinery leads
to the persistence of viral antigen production, which, in turn,
progressively exacerbates the functional failure of the immune
response; the immune response represents the most effective tool
for viral control [6].
A CHB “cure” can be deﬁned at different levels. Basically, the
most desirable end point is the elimination of both the viraemia
(HBV-DNA) and the viral surface antigen (HBsAg), followed by sero-
conversion to anti-HBsAg (anti-HBs) antibodies [7]. This condition
is largely satisfactory because it is associated with a substantial
improvement of outcomes and a reduced risk of developing compli-
cations, at least in non-cirrhotic patients [8–10]. A complete cure,
however, would only be accomplished by elimination of cccDNA
from infected hepatocytes, which represents deﬁnite viral eradica-
tion and ensures protection from the risk of reactivation in the case
of immunosuppression [11] (Fig. 1).
However, both of these endpoints still represent a challenge
because they are not adequately met  by current therapies. There-
fore, clinicians must rely on a surrogate but more realistic end point,
which is the induction of sustained virological remission [1,12].
The current research aimed at designing new strategies for
HBV “elimination” focuses on the following two  main assumptions
derived from the known mechanisms underlying viral persistence:
(a) The need to target the virus directly and/or (b) the need to
restore an effective immune response.2. Current HBV therapies
Two different therapeutic approaches are currently available for
patients with CHB: (1) a ﬁnite antiviral and immunomodulatory
 rights reserved.
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Aig. 1. Schematic representation of the potential curative approaches for chronic h
ucleos(t)ide analogues; DCs, dendritic cells; TLRs, Toll-Like Receptors; RNAi, RNA 
reatment with interferon-; and (2) an indeﬁnite treatment with
ucleos(t)ide analogues (NAs), which can successfully achieve non-
urative suppression of viral replication [1] (Fig. 2).
Treatment with pegylated interferon- (PEG-IFN2a) can have
 curative effect mediated by viral inhibition and an enhancement
f the host immune response. Unfortunately, a curative effect of
EG-IFN2a is observed in fewer than 10% of patients, regardless
f HBeAg status [13,14].
A better deﬁnition of the factors that predict the response,
uch as HBsAg levels, viral genotypes, and HBeAg levels for
he HBeAg-positive population, and validation of the stopping
ules will most likely result in better selection of the patients
o be treated, which, in turn, will lead to higher rates of treat-
ent response [15]. However, these optimization attempts wouldead to improved effectiveness of PEG-IFN therapy based on
he exclusion of patients with unfavourable features; conse-
uently, this strategy would not impact the overall cure rates for
HB.
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Since the introduction of lamivudine in 1998, four other agents
with progressively higher antiviral activity and a more efﬁcient
genetic barrier to drug resistance have been approved. These
drugs successfully achieve satisfactory HBV DNA suppression rates,
which are stably maintained with third-generation NAs (entecavir
and tenofovir), at least based on the data acquired to date [16,17]
(Fig. 2).
NAs inhibit HBV DNA synthesis via a competitive interaction
with the natural substrates of the HBV polymerase; however, they
do not interfere with cccDNA formation (Fig. 1). As a consequence,
in most patients, HBV replication rebounds after antiviral therapy
is discontinued.
Based on these ﬁndings, is it possible to achieve signiﬁcant CHB
cure rates with these agents? The currently available data would
suggest otherwise: HBsAg seroclearance is considered a rare event
during NA therapy; this event is observed in only 0.5–1% of all
treated patients per year. The rate of decline of serum HBsAg lev-
els is such that, according to mathematical models, a complete
2012-
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limination could theoretically be achieved in a time frame of
0–30 years [18,19].
This effect could be expected for both HBeAg-positive and
BeAg-negative CHB. In fact, although the rate of decline of HBsAg
evels is more pronounced in HBeAg-positive patients, the baseline
BsAg levels are usually higher in HBeAg-positive than in HBeAg-
egative patients.
This approach could improve in the future, once adequate data
n the use of the most potent NAs are available and the thera-
eutic strategies are optimized through the use of new tools for
onitoring treatment outcomes [20].
Certainly, prolonged viral remission is the sine qua non for the
esign of new treatment possibilities, because although remission
ypically occurs slowly, it triggers the necessary mechanisms lead-
ng to the end of viral control. In support of this hypothesis, cccDNA
evels signiﬁcantly decrease after NA therapy [11,21], and pro-
onged NA-induced viral remission is able to restore the function
f HBV-speciﬁc T cells [22].
Based on this hypothesis, combination treatments capable of
oosting anti-HBV reactivity while steadily suppressing viral repli-
ation are expected to accelerate the decline in HBsAg levels. Thus,
he administration of PEG-IFN2a, once complete suppression of
BV replication has been obtained with NAs, represents the newest
herapeutic approach currently being evaluated [23,24].
. New approaches
.1. The viral target
As described earlier, treatment of CHB requires the elimina-
ion or molecular inactivation of the intrahepatic cccDNA pool.
hether this approach is clinically achievable remains an open
uestion; at present, preclinical studies are evaluating a number
f compounds (restriction enzymes and sulfonamide inhibitors)
ith highly promising results [25,26]. The recent ﬁnding that IFN
nd members of the TNF family induce cccDNA degradation in a
peciﬁc (without affecting the host genome) and non-cytopathic
ashion seems to be an important milestone [27]. However, the
otent antiviral activity of IFN shown in this model does not ﬁt
ith the CHB cure rate observed for PEG-IFN in clinical practice.
ne can speculate that larger amounts of IFN (similar to the lev-
ls used in these highly complex in vitro models) are required
o achieve cccDNA degradation or that the formulation and man-
er of administration of IFN currently used in clinical practice
xploits only a minimal portion of its biological potential. This
ypothesis is supported by the ﬁnding that the delivery of IFN to
BV-infected liver cells via HBV-positive T-cell receptor-like anti-
odies can induce an effective and robust response, thus setting up a
elivery system that is potentially suitable for other cytokines [28].
aken together, these ﬁndings suggest that cytokines with antiviral
ctivity could continue to represent the backbone of CHB therapy
nce their use is optimized.
A possible alternative to cccDNA elimination is either its direct
unctional inactivation or the prevention of its transcription (Fig. 1).
he most intriguing approaches in this ﬁeld involve epigenetic
odiﬁcations [29]. Furthermore, RNA interference (RNAi) has been
hown to potently block viral mRNA [30,31]. However, the possi-
ility of translating these proofs of concept into the clinical arena
urrently is still distant.
Another stage of the viral life cycle that could represent a target
f therapy is viral capsid assembly and, ultimately, virion secre-
ion. Along this line, a series of compounds have been investigated,
ncluding heteroarylpyrimidines (HAPs) and phenylpropenamides;
owever, they appear to still be in the preclinical stage of devel-
pment. Regarding viral secretion, recent data have reported theDisease 47 (2015) 836–841
effectiveness of alisporivir in reducing HBV replication and HBsAg
secretion in in vitro models [32].
A novel approach that is currently under investigation in cancer
and infectious diseases is targeting of IAP (inhibitor of apoptosis
protein), with the goal of inducing apoptosis in virally infected
cells. After encouraging results from in vitro and animal models,
an antagonist of the IAP protein, birinapant, is currently in a phase
I clinical trial in patients with chronic HBV.
An approach that is potentially closer to clinical translation
entails interfering with the earliest stage of the viral cell cycle by
blocking viral entry.
Studies of HBV vaccination [32] and the optimal coverage
required to provide sterilizing immunity to HBV as well as studies
of the use of passive prophylaxis to prevent graft reinfection after
liver transplantation for CHB-related disease [33] have conﬁrmed
that anti-HBsAg contains a neutralizing antibody component.
Further studies have identiﬁed the pre-S1 domain of the HBV-L
protein to be the essential component of viral infectivity; its criti-
cal role is due to the interaction between HBsAg and receptors on
the hepatocyte surface [34,35]. These results have recently been
corroborated by the identiﬁcation of a bile salt transporter in hepa-
tocytes (NTCP) that functions as a high-afﬁnity receptor for HBV
and HDV [36].
The conﬁrmation that HBV exhibits a selective tissue-speciﬁc
(and species-speciﬁc) tropism strongly suggests, once again, that
HBV infection is an ideal candidate for entry inhibitor compounds
(Fig. 1 and Table 1). Based on these assumptions, ﬁne mapping of
the L protein sequence, which is critical for HBV infectivity, led to
the selection of a myristoylated peptide containing amino acids 2
to 48 of the L protein (Myrcludex B), which is currently in clinical
development. After validation in in vitro studies [37], Myrcludex B
was shown to completely abrogate the infection [38] at low doses
and to inhibit viral spread in already-established infections, thus
preventing the infection of naïve hepatocytes [39].
Myrcludex B has been proven to be highly selective in targeting
hepatocytes, has passed acute and long-term toxicity studies, and is
currently in phase II clinical trials in chronically HBV/HDV-infected
patients (Table 1).
Although expectations for these impending results are high,
some remarks should be made. The signiﬁcance of this approach
appears to be immediately relevant in selected settings, such as
preventing graft reinfection after liver transplantation or limiting
the viral spread in acute hepatitis.
However, it is more difﬁcult to foresee its efﬁcacy in the context
of well-established CHB, which is known to be a highly efﬁcient
infection; at the chronic stage, virtually all hepatocytes are infected.
Certainly, to be effective in CHB, this approach must rely on hep-
atocyte turnover, which, in turn, is dependent on the ability of the
host immune response to clear the infected hepatocytes.
Considering the natural half-life of hepatocytes and the absence
of a system to reinforce the immune-mediated turnover, a signiﬁ-
cant beneﬁcial effect of this approach in CHB is not predictable, and
important safety concerns must be considered.
3.2. Immunotherapeutic approaches
Spontaneous HBsAg seroclearance after the acute phase, which
is observed in more than 90% of patients who encounter the virus as
adults, occurs through the development of a robust innate or adap-
tive immune response. Conversely, CHB results from an inability
to mount a sufﬁciently strong immune reaction, which, over time,
is worsened by the persistent exposure to high amounts of viral
antigens, ultimately leading to a complete functional exhaustion
or deletion of the HBV(+) T cells [6,40].
Thus, mimicking the immune events that occur during self-
limiting HBV infection represents a feasible approach to treating
E. Loggi et al. / Digestive and Liver Disease 47 (2015) 836–841 839
Table  1
Ongoing clinical trials (partial source: www.clinicaltrials.gov) or recently completed clinical trials evaluating new compounds (alone or in association with already approved
CHB  drugs).
Class Compound Target Status of development
Peptide PA-44 CHB Phase II
Therapeutic vaccine Double-plasmid DNA vaccine HBeAg-positive CHB Phase II
Cytokines/immunostimulating IFN-a CHB Phase II
Therapeutic vaccine Naked DNA vaccine (pCMVS2.S) CHB Phase I/II
Therapeutic vaccine ABX 203 (HBs and HBc antigens) CHB Phase II/II
Vaccine/immunological/growth factors HBIG + GM-CSF + HBV Vaccine HBeAg-negative CHB Phase I/II
Therapeutic vaccine/immunostimulating GS-4774 (engineered multi-genotype) CHB Phase II
Immunostimulating GS-9620 (TLR-7 agonist) CHB Phase I/II
Cytokines/antivirals Pegylated Interferon Lambda HBeAg-positive CHB Phase II
Peptide/entry inhibitors Myrcludex B (preS1-derived lipopeptide) CHB Phase II
Immunostimulating Thymosin- CHB (cirrhosis) Phase IV
Apoptosis inhibitor Birinapant (IAP antagonist) CHB Phase I
Antivirals NVR 3-778 (core inhibitor) CHB Phase Ia
Viral  transcription inhibitors ARC-520 (siRNAs) CHB Phase II
CHB, chronic hepatitis B; HBIG, hepatitis B immune globulin; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-, interferon-gamma; HBeAg, hepatitis e
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a Updated information not available; unknown study progress.
HB. This strategy involves restoration of proper immune function,
hich is lost at the chronic stage [41], and it represents the most
idely explored strategy to date.
Attempts to cure CHB by therapeutic vaccination have produced
isappointing results, at least with the ﬁrst formulations. The main
rawback of this strategy is most likely that it aims to target and
oost anti-envelope speciﬁcities, which have been proven to target
he subset of HBV-positive cells that are more rare in the circulat-
ng compartment of patients with CHB [42,43]. To overcome these
imitations, other strategies are exploring the use of different anti-
ens to elicit a wider and multispeciﬁc response, while also making
se of advanced technologies (Table 1). In particular, the core anti-
en is the most frequent speciﬁcity in CHB and it is also positively
orrelated with better control of infection [42]. Therefore, the ther-
peutic potential of vaccines that target the core protein is currently
nder evaluation on the basis of encouraging results obtained in the
reclinical phase [44].
Currently, these data are limited to animal models; therefore,
heir translation into CHB therapy will most likely require more
ime [45–57].
More direct and sophisticated approaches involve cell-therapy
trategies, which are based on the use of different types of engi-
eered T cells. These T cells are genetically modiﬁed to express a
redeﬁned antiviral speciﬁcity; the rationale for this procedure is
o replace or reinforce the pool of absent or functionally weak host
 cells with a new pool of perfectly functional T cells, while also tar-
eting the immunodominant epitopes associated with viral control
48,49].
These types of procedures, albeit innovative, have already
eached the clinical setting, and they are under evaluation, in par-
icular, in the context of malignant disease or virus-associated
alignant disease [50,51].
The appeal of using this immunotherapy is immediately evi-
ent: manipulation of these cells facilitates the treatment tailoring
o the patient (considering his or her HLA status and providing
n antiviral speciﬁcity that is completely missing). Furthermore,
ith the progressively increasing use of this approach in the onco-
aematological ﬁeld, we are gaining conﬁdence in the idea of
xploiting this technological progress.
Thus, this strategy could lead to a cure for CHB. However, sev-
ral points must be addressed to establish its effectiveness and
afety in the setting of CHB: ﬁrst, very strong activation of T-
ell-mediated killing can result in hepatitis ﬂares of unknown
onsequence; second, it must demonstrated that the engineered
 cells do not undergo the same mechanisms of functionalexhaustion as natural T cells due to circulating antigens and given
the pro-immunotolerant environment of the liver.
Another potential strategy to boost the antiviral T cell response
expected to produce results involves manipulation of the inhibitory
receptors that belong to the extended CD28/CTLA-4 family of T-
cell regulators (Fig. 1). The rationale for the use of this approach
is based on repeated observations that these molecules, PD-1 in
particular, are highly expressed on both peripheral and intrahep-
atic HBV-speciﬁc T cells and that manipulation of these pathways,
via either the stimulatory or the inhibitory receptors, can restore
antiviral function [52–54]. According to these data, the expres-
sion of inhibitory receptors has become a measure of functional
weakness, which is responsible for the lack of immune control.
Once again, knowledge gained from their pioneering use in the
treatment of malignancy will beneﬁt their potential use in CHB, as
cancer and chronic viral infections share the common mechanism
of using immune checkpoint pathways to strongly downregulate
T-cell activation [55].
This approach started with ipilimumab, which was approved
by the Food and Drug Administration (FDA) in 2011 for advanced
melanoma, and other checkpoint agents continue to be devel-
oped, including PD-1 and PD-L1 inhibitors, which are currently
being tested alone or in combination with different formulations
across multiple tumour types [56,57]. Research in this speciﬁc ﬁeld
currently represents a very innovative topic, according to the clin-
icaltrials.gov registry.
In terms of viral hepatitis, no data are available for the treat-
ment of CHB; however, the anti-PD1 antibody was evaluated in
the treatment of patients with chronic hepatitis C, with apparently
modest therapeutic results. However, the clinical signiﬁcance of
this study is limited due to the small patient population and, more
importantly, the use of a single dose of anti-PD1 [58].
The development of this approach as a cure for CHB is par-
ticularly attractive given its high biological potential and the
advantages over other immunotherapy strategies, such as the engi-
neered T cells described earlier; this approach does not require a
demanding and invasive procedure, and it boosts the preexisting
response, thereby eliminating the risk of cross-reactivity or side
effects from genetic modiﬁcation (i.e., lymphoproliferative disor-
ders). However, major safety concerns arise from manipulation
of the patterns of physiological immune checkpoints, such as the
possibility of developing autoimmune manifestations; therefore,
an attempt to disrupt the physiological tolerance to render the
mechanism effective against antiviral reactivity requires careful
evaluation before implementing this approach in clinical practice.
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In addition to immunotherapy based on manipula-
ion/stimulation of adaptive immunity, recent studies have
ocused on the pathways of innate immunity, which play a key
ole in the control of infection. Activation of the innate immune
esponse also stimulates adaptive immunity; therefore, this strat-
gy is expected to have wider effects on the immune control of
HB.
To translate this basic rationale to a clinical cure for CHB, recent
tudies have attempted to trigger the innate response by targeting
oll-like receptors (TLRs), which are pattern-recognition recep-
ors (PRRs) capable of recognizing conserved pathogen-associated
olecular patterns (PAMPs).
Downregulation of the expression of TLRs on HBV-infected
epatocytes has been shown to be a possible mechanism of
mmune evasion [59]; the use of TLR agonists could therefore
eestablish proper immune function [60]. Recently, a TLR7 agonist
GS-9620) was developed, and it demonstrated sustained reduction
f viraemia and antigenemia in animal models of CHB [61,62].
GS-9620 is a new therapeutic strategy approaching clinical use,
s it is in clinical phase I/II studies (Table 1).
. Conclusion
The unsuccessful CHB cure rates achieved with the current treat-
ents make the development of new therapeutics mandatory. The
evelopment of new antiviral therapies, combined with the excel-
ent results obtained with the vaccination policy, could lead to
he control of HBV infection and possibly eradication in the near
uture.
Multiple efforts at different levels are under way  to achieve this
oal; some efforts are focused on HBV virology, whereas others are
valuating the feasibility of boosting the immune response.
CHB therapy appears unchanged when compared with the
emarkable improvement in patients with chronic hepatitis C, as
t continues to rely on the same strategies of a decade ago (inter-
eron and nucleos(t)ide analogues). However, on examining these
dvances in depth, this statement is not completely true; these
gents have been progressively optimized, and they will further
mprove in the near future. At the same time, signiﬁcant advance-
ents have been made in the understanding of HBV virology and
he features of immunological impairment. All of these ﬁndings
rive researchers to develop new strategies, while also learning
rom other models of viral infection and the newest cancer thera-
ies.
The primary end point of the more recent strategies currently
nder evaluation is to cure CHB. However, the CHB model is a highly
omplex model of infection, and the development of new strategies
ill face some important issues.
A simpliﬁcation of these problems includes the need to be highly
elective, for approaches that directly target the virus; instead,
or approaches that target the host immune response, it is neces-
ary to avoid the severe side effects associated with the disruption
f immunotolerance. Further complicating this scenario, ideally,
hese two distinct approaches, if used in combination, require an
dditive or even synergistic activity against HBV. The rationale of a
ulti-target approach, which is already under evaluation in current
rials, is given by multiple, specular evidences. First, the restoration
f immune response involves a stage of complete or partial inhi-
ition of viral replication, in turn decreasing antigenemia. On the
ther hand, virological inhibition should be able to prevent infec-
ion of new cells, but complete “clearance” of infected hepatocytes
annot be achieved unless successful T-cell-mediated elimination
akes place. Both of these issues make “curing CHB in 100% of
atients” an ongoing challenge, and the therapeutic translation of
ew knowledge is not achievable in the short-term.
[Disease 47 (2015) 836–841
However, many milestones in understanding the biology of HBV
have been achieved in recent years, which means that we are cur-
rently experiencing a new trend in acquisition of knowledge in the
ﬁeld. Once these new studies are completed in the coming few
years, a completely new scenario will be at hand.
Conﬂict of interest
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